Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply

Carlos Taxonera; Iñigo Sagastagoitia; Cristina Alba; Norberto Mañas; David Olivares; Enrique Rey

doi:10.1111/apt.15893

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply

Aliment Pharmacol Ther. 2020 Aug;52(3):571-572. doi: 10.1111/apt.15893. Epub 2020 Jun 25.

Authors

Carlos Taxonera¹, Iñigo Sagastagoitia², Cristina Alba¹, Norberto Mañas¹, David Olivares¹, Enrique Rey¹

Affiliations

¹ Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos [IdISSC], Madrid, Spain.
² Department of Internal Medicine, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos [IdISSC], Madrid, Spain.

Abstract

LINKED CONTENT

This article is linked to Taxonera et al an Garg et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15814.

Publication types

Letter
Comment